PreveCeutical Medical Inc. announced that it plans to commence exploratory discussions with pharmaceutical and biotechnology companies developing therapies for neurological disorders, that are seeking a targeted nose-to-brain drug delivery system in connection with same, with the intention of forming a partnership for the co-development of the Company's soluble gel ('Sol-gel') system. The company has previously demonstrated effective delivery and retention of its Sol-gels to the olfactory epithelium in an adult human nasal cast using its custom applicator device. PreveCeutical now believes that this system may be of value to companies interested in delivering pharmaceuticals to the central nervous system (CNS). PreveCeutical believes that the pharmaceutical industry faces significant challenges in delivering drugs to the brain, and that this can be a major obstacle in successfully developing effective treatments for neurological disorders. Starting a dialogue with potential partners will assist PreveCeutical in gauging the potential value of its nose-to-brain delivery approach, and in assessing whether partnership opportunities exist.